ImmuCell Corporation Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
ImmuCell Corporation (ICCC) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $4.81 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.84.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2017-03-31 was $5.25.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $4.81.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $4.69, a 23.49% decline from fiscal 2022.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $6.13, a 13.42% decline from fiscal 2021.
- ImmuCell Corporation share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $7.08.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $4.81 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $4.81 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $4.69 10-K · filed 2025-03-28 | |||
| 2022-12-31 | $6.13 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $6.13 10-Q · filed 2022-11-21 | |||
| 2022-06-30 | $6.13 10-Q/A · filed 2022-11-21 | |||
| 2022-03-31 | $5.84 10-Q/A · filed 2022-11-21 | |||
| 2021-12-31 | $7.08 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $7.08 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $7.08 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $3.15 10-Q/A · filed 2022-11-21 | |||
| 2017-12-31 | $3.47 10-K · filed 2018-03-29 | |||
| 2017-09-30 | $4.13 10-Q · filed 2017-11-13 | |||
| 2017-06-30 | $5.25 10-Q · filed 2017-08-14 | |||
| 2017-03-31 | $5.25 10-Q · filed 2017-05-11 | |||
| 2016-12-31 | $5.59 10-K · filed 2018-03-29 | |||
| 2015-12-31 | $4.29 10-K · filed 2017-03-30 | |||
| 2014-12-31 | $3.15 10-K · filed 2015-03-26 | |||
| 2013-12-31 | $3.11 10-K · filed 2015-03-26 | |||
| 2012-12-31 | $3.39 10-K · filed 2015-03-26 | |||
| 2011-12-31 | $4.79 10-K · filed 2014-03-26 | |||
| 2010-12-31 | $2.00 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |